Pharmabiz
 

ADA enters strategic agreement with Quintiles’ Digital Patient Unit

Research Triangle Park, NCSaturday, April 7, 2012, 14:00 Hrs  [IST]

Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, and the American Diabetes Association (ADA) have entered into a strategic agreement in which Quintiles’ Digital Patient Unit will provide the ADA’s millions of website users access to Quintiles’ medication monitoring service.

The ADA’s constituents who opt in for the service will receive free safety checks of their medications to identify potential interactions and other risk factors, which are already provided to the 2.5 million registered users of Quintiles’ www.MediGuard.org. Registrants will also be eligible to participate in select direct-to-patient programs to benefit their medical conditions and advance global diabetes patient care.

“We are very pleased to offer this medication monitoring service to improve the lives of all people affected by diabetes,” said Vivian Fonseca, MD, president, Medicine & Science, American Diabetes Association. “This collaboration with Quintiles enables the Association to provide important safety information at no cost to our constituents”.

The ADA’s constituents may opt in to this service from the Association’s website www.Diabetes.org. All registrant data will reside on Quintiles’ privacy-safe, Digital Patient Platform. Quintiles’ Digital Patient Unit will manage the patient relationships from this platform, continuously providing up-to-date medication safety information and introducing members to direct-to-patient clinical research, observational studies and disease management opportunities.

Quintiles’ David Coman, senior vice president communication and patient recruitment, echoed Dr. Fonseca’s sentiments. “This relationship between Quintiles and the American Diabetes Association illustrates the manner in which associations help promote better health outcomes for their members or constituents,” Coman said. “The very first pharma project undertaken by our founder involved a diabetes treatment, so it is fitting that we are innovating in this area once again on our 30-year anniversary."

Quintiles’ Digital Patient Unit (DPU) was formed in January 2012 to provide patients with information to better manage their personal health and provide them with opportunities to participate in clinical research, observational studies and programmes to better manage their conditions.

 
[Close]